{"id":"am0010","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, AM0010 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"AM0010 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:39.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT03382899","phase":"PHASE2","title":"Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2018-03-19","conditions":"Non Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT02923921","phase":"PHASE3","title":"Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-01","conditions":"Pancreatic Cancer","enrollment":567},{"nctId":"NCT03382912","phase":"PHASE2","title":"Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2018-03-22","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT03554434","phase":"","title":"An Expanded Access Program for AM0010 (Pegilodecakin)","status":"NO_LONGER_AVAILABLE","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":""},{"nctId":"NCT04194892","phase":"PHASE1","title":"A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-01-19","conditions":"Healthy","enrollment":12},{"nctId":"NCT03381547","phase":"PHASE1","title":"A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-18","conditions":"Healthy Adult Subjects","enrollment":12},{"nctId":"NCT03267732","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-09-05","conditions":"Healthy Adult Subjects","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY3500518","Pegilodecakin"],"phase":"phase_2","status":"active","brandName":"AM0010","genericName":"AM0010","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Biologic","firstApprovalDate":"","aiSummary":"AM0010 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}